SCHEMBL12100490

SCHEMBL12100490

COC(=O)c1ccc2nc(-c3ccc(F)cc3F)c(N3CCCCC3C)nc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
GAA P10253 2/20 0.40
S1PR1 P21453 3/20 0.40
LMNA P02545 2/20 0.38
HIF1A Q16665 1/20 0.38
NAMPT P43490 7/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TNF P01375 1/20 0.38
NR2F2 P24468 1/20 0.38
HTT P42858 1/20 0.38
MCL1 Q07820 1/20 0.38
KLF5 Q13887 1/20 0.38
NOD1 Q9Y239 1/20 0.38
IDH1 O75874 2/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12100492 1.00 MAPT (0.40) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100828 0.97 NAMPT (0.38) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100829 0.97 NAMPT (0.38) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100336 0.90 HPGD (0.38) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100587 0.90 HPGD (0.38) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100347 0.89 S1PR1 (0.40) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100345 0.89 S1PR1 (0.40) MAPTALDH1A1HPGDGAAS1PR1
SCHEMBL12100300 0.88 NAMPT (0.47) MAPTALDH1A1HPGDGAANAMPT
SCHEMBL12100259 0.87 HPGD (0.39) MAPTALDH1A1HPGDGAANAMPT
SCHEMBL12100263 0.87 HPGD (0.39) MAPTALDH1A1HPGDGAANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2681207-B1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2016-12-28 EP disclosed
US-8912188-B2 Substituted quinoxaline carboxylic acids for the inhibition of PASK BIOENERGENIX, LLC (US) 2014-12-16 US disclosed
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK PASK, PDXK, PANK2 MAPT 3629/4885ALDH1A1 3714/4885HPGD 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.